舒芬太尼腰硬膜联合治疗重症癌痛的临床疗效观察

目的：观察舒芬太尼腰硬膜联合治疗重症癌痛的临床效果。方法选取晚期癌痛患者48例，随机分为观察组和对照组，各24例。观察组给予腰硬膜联合治疗，以舒芬太尼和罗哌卡因先行蛛网膜下隙注射，再行硬膜外镇痛；对照组给予单纯硬膜外镇痛。比较2组患者镇痛效果包括治疗前、用药后30 min、持续性、暴发性VAS评分以及总体满意度。结果2组患者治疗前、用药后30 min、持续性VAS评分比较差异无统计学意义（P＞0．05），观察组暴发性VAS评分明显低于对照组（P＜0．05）；观察组总体满意度明显高于对照组（P＜0．05）。结论舒芬太尼腰硬膜联合治疗重症癌痛可有效降低暴发痛VAS评分，提高患者总体满意度，值得临床推广应用。

Clinical Effects of Combined Spinal Epidural Sufentanil for Severe Cancer Pain

Objective To observe the clinical effects of combined spinal epidural sufentanil in the treatment of severe cancer pain .Methods 48 cases of advanced cancer patients were randomly divided into the observation group and the control group ,24 cases in each .The observation group were given combined spinal epidural treatment ,with sufentanil and ropivacaine first subarachnoid space injection ,epidural analgesia;epidural analgesia was given to the control group .The analgesic effects of the 2 groups were compared before and after treatment for 30 min,continuous of VAS score and overall satisfaction .Results The 2 groups of patients before treatment ,after treatment for 30 min,continuous of VAS score ,the difference had no statistical signifi-cance(P>0.05),outbreak VAS score of the observation group was significantly lower than that of the control group (P<0.05);overall satisfaction of the observation group was significantly higher than that of the control group (P<0.05).Conclusion Sufentanil epidural combination therapy for severe cancer pain can effectively reduce persistent pain and outbreak VAS score ,im-prove overall satisfaction of patients ,and it is worthy of clinical application .